COVID-19 is an inflammatory hypercytokinemia  disease. The aim of therapy is prevention of viral replication and controlling the inflammatory process. On February 09, 2021 FDA approved emergency use authorization of monoclonal antibodies including bamlanivimab and etesevimab for mild to moderate covid-19 patients who are high risk for progression of disease ( age > 65years, medical comorbidities).
These treatments focus on long COVID syndrome:
Cognitive behavioral therapy
COVID-19 non-medical therapy
COVID-19 medical therapy
Babesiosis medical therapy
COVID-19 secondary prevention
Avian influenza medical therapy
Measles medical therapy
COVID-19 interventions
Middle East respiratory syndrome coronavirus infection medical therapy